| 2025-02-28 |
股东大会：
将于2025-04-11召开股东大会
会议内容 ▼▲
- 1.The issuance of Series I preferred investment options and placement agent options issued in connection therewith, and shares of common stock underlying such options, issued in connection with an offering and sale of securities of the Company that was consummated on February 11, 2025, for purposes of complying with Nasdaq listing rule 5635(d) and satisfying our contractual obligations to the holders of such options (the “Issuance Proposal”);
2.An amendment to the Company’s Certificate of Incorporation, as amended and/or restated from time to time (the “Certificate of Incorporation”), to increase the total number of shares of common stock authorized for issuance (the “Increase Proposal”);
3.To approve one or more adjournments of the Special Meeting, if necessary or appropriate, to solicit additional proxies in favor of the Issuance Proposal and/or the Increase Proposal, if there are not sufficient votes at the Special Meeting to approve and adopt the Issuance Proposal or the Increase Proposal (the “Adjournment Proposal”).
|
| 2025-02-11 |
详情>>
股本变动：
变动后总股本3474.45万股
变动原因 ▼▲
- 原因：
- Common Stock Offered 6,103,289 shares by the company
|
| 2024-11-13 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.53美元,归母净利润-805.1万美元,同比去年增长-6.13%
|
| 2024-11-06 |
股东大会：
将于2024-12-17召开股东大会
会议内容 ▼▲
- 1.The election of two Class III directors to the Board of Directors of the Company to serve until the 2027 Annual Meeting of Shareholders;
2.The approval of an amendment to the Company’s 2020 Omnibus Performance Award Plan, to increase the number of authorized shares of common stock reserved for issuance by 600,000, from 2,020,652 to 2,620,652;
3.The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2024;
4.To transact such other and further business as may properly come before the meeting or any adjournment thereof.
|
| 2024-08-14 |
详情>>
业绩披露：
2024年中报每股收益-0.33美元,归母净利润-483.6万美元,同比去年增长5.91%
|
| 2024-05-15 |
详情>>
业绩披露：
2024年一季报每股收益-0.17美元,归母净利润-237.1万美元,同比去年增长16.89%
|
| 2024-03-27 |
详情>>
业绩披露：
2023年年报每股收益-1.05美元,归母净利润-1074万美元,同比去年增长18.44%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.79美元,归母净利润-758.6万美元,同比去年增长25.41%
|
| 2023-09-19 |
股东大会：
将于2023-11-02召开股东大会
会议内容 ▼▲
- 1.The election of two Class II directors to the Board of Directors of the Company to serve until the 2026 Annual Meeting of Shareholders;
2.The approval of an amendment to the Company’s 2020 Omnibus Performance Award Plan, to increase the number of authorized shares of common stock reserved for issuance by 600,000, from 1,420,652 to 2,020,652;
3.The approval of a non-binding advisory resolution supporting the compensation of the Company’s named executive officers;
4.The approval of a non-binding advisory resolution regarding the frequency of future non-binding advisory votes related to future named executive officer compensation;
5.The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2023;
6.To transact such other and further business as may properly come before the meeting or any adjournment thereof.
|
| 2023-08-14 |
详情>>
业绩披露：
2023年中报每股收益-0.6美元,归母净利润-514万美元,同比去年增长23.31%
|
| 2023-05-24 |
复牌提示：
2023-05-23 15:24:53 停牌，复牌日期 2023-05-23 15:29:53
|
| 2023-05-17 |
详情>>
业绩披露：
2023年一季报每股收益-0.36美元,归母净利润-285.3万美元,同比去年增长10.54%
|
| 2023-03-31 |
详情>>
业绩披露：
2022年年报每股收益-1.81美元,归母净利润-1316.8万美元,同比去年增长-16.4%
|
| 2022-11-14 |
详情>>
业绩披露：
2022年三季报(累计)每股收益-1.43美元,归母净利润-1017万美元,同比去年增长-36.44%
|
| 2022-08-15 |
详情>>
业绩披露：
2022年中报每股收益-0.94美元,归母净利润-670.2万美元,同比去年增长-36.8%
|
| 2022-08-08 |
股东大会：
将于2022-09-21召开股东大会
会议内容 ▼▲
- 1.The election of three Class I directors to the Board of Directors of the Company to serve until the 2025 Annual Meeting of Shareholders;
2.The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2022;
3.To transact such other and further business as may properly come before the meeting or any adjournment thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-08-18 |
股东大会：
将于2021-09-29召开股东大会
会议内容 ▼▲
- 1.The election of two Class III directors to the Board of Directors of the Company to serve until the 2024 Annual Meeting of Shareholders;
2.The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2021;
3.To transact such other and further business as may properly come before the meeting or any adjournment thereof.
|
| 2020-07-31 |
股东大会：
将于2020-09-01召开股东大会
会议内容 ▼▲
- 1.The election of two Class II directors to the Board of Directors of the Company to serve until the 2023 Annual Meeting of Shareholders;
2.The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2020;
3.The approval of a non-binding advisory resolution supporting the compensation of the Company’s named executive officers;
4.To approve the Microbot Medical Inc. 2020 Omnibus Performance Award Plan;
5.To transact such other and further business as may properly come before the meeting or any adjournment thereof.
|
| 2019-08-09 |
股东大会：
将于2019-09-10召开股东大会
会议内容 ▼▲
- 1.The election of three Class I directors to the Board of Directors of the Company to serve until the 2022 Annual Meeting of Shareholders;
2.The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2019;
3.To approve an amendment to our certificate of incorporation, as amended, to effect a reduction in the authorized number of shares of capital stock the Company is authorized to issues from 221,000,000 to 61,000,000, including a reduction in the number of authorized shares of common stock of the Company from 220,000,000 to 60,000,000;
4.To transact such other and further business as may properly come before the meeting or any adjournment thereof.
|
| 2018-12-31 |
详情>>
内部人交易：
Mona Joseph共交易5笔
|
| 2018-09-04 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2018-07-26 |
股东大会：
将于2018-09-04召开股东大会
会议内容 ▼▲
- 1.The election of two Class III directors to the Board of Directors of the Company to serve until the 2021 Annual Meeting of Shareholders;
2.The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2018;
3.To approve an amendment to our certificate of incorporation to effect a reverse stock split, at a ratio of not less than one-for-five (1:5) and not greater than one-for-twenty (1:20), of the common stock of the Company (the “Reverse Split”), which will be determined by the Board of Directors in its sole discretion;
4.To transact such other and further business as may properly come before the meeting or any adjournment thereof.
|
| 2017-08-11 |
股东大会：
将于2017-09-12召开股东大会
会议内容 ▼▲
- 1. The election of two Class II directors to the Board of Directors of the Company to serve until the 2020 Annual Meeting of Shareholders;
2. The ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the Company’s independent registered public accounting firm for the year ending December 31, 2017;
3. To approve the Microbot Medical Inc. 2017 Equity Incentive Plan;
4. The approval of a non-binding advisory resolution supporting the compensation of the Company’s named executive officers;
5. The approval of a non-binding advisory resolution regarding the frequency of future non-binding advisory votes related to future named executive officer compensation;
6. To transact such other and further business as may properly come before the meeting or any adjournment thereof.
|
| 2016-11-29 |
详情>>
拆分方案：
每9.0000合并分成1.0000股
|
| 2016-10-28 |
股东大会：
将于2016-11-14召开股东大会
会议内容 ▼▲
- 1. To approve and adopt the Agreement and Plan of Merger and Reorganization, dated as of August 15, 2016 (the “Merger Agreement”), by and among StemCells, Microbot and C&RD Israel Ltd., a wholly owned subsidiary of StemCells (“Merger Sub”), and approve the transactions contemplated thereby;
2. To approve the issuance of StemCells common stock, par value $0.01 per share, in connection with the Merger to advisors and to shareholders of Microbot, in each case as contemplated by the Merger Agreement;
3. To amend StemCells’ restated certificate of incorporation to effect a reverse stock split of StemCells’ issued and outstanding common stock within the range of one-for-three to one-for-eleven (with the exact amount to be determined by StemCells’ Board of Directors prior to the completion of the Merger);
4. To amend StemCells’ restated certificate of incorporation to increase the number of authorized shares of StemCells common stock from 200,000,000 to 220,000,000 shares;
5. To amend StemCells’ restated certificate of incorporation to change the name of StemCells from “StemCells, Inc.” to “Microbot Medical Inc.”;
6. To approve the adjournment of the StemCells special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal Nos. 1, 2, 3, 4, or 5;
7. To conduct any other business as may properly come before the StemCells special meeting or any adjournment or postponement thereof.
|
| 2016-05-10 |
详情>>
拆分方案：
每12.0000合并分成1.0000股
|
| 2016-04-08 |
股东大会：
将于2016-05-05召开股东大会
会议内容 ▼▲
- 1. to elect the two Class I directors named in the accompanying proxy materials to serve until the 2019 Annual Meeting of Stockholders;
2. to consider and vote upon a proposal to ratify the selection of Grant Thornton LLP as independent public accountants for the company for the fiscal year ending December 31, 2016;
3. to approve an amendment to the company’s certificate of incorporation to effect a reverse stock split of the company’s issued and outstanding common stock, as further described in Proposal Number 3;
4. to approve an amendment to the company’s certificate of incorporation to reduce the number of authorized shares of common stock from 225 million to 200 million;
5. to approve the sale by the company of up to $16 million in company common stock, in accordance with a committed equity line purchase agreement, as further described in Proposal Number 4;
6. to transact any and all other business that may properly come before the meeting.
|
| 2015-04-30 |
股东大会：
将于2015-06-11召开股东大会
会议内容 ▼▲
- 1. to elect the two Class III directors named in the accompanying proxy materials to serve until the 2018 Annual Meeting of Stockholders;
2. to consider and vote upon a proposal to ratify the selection of Grant Thornton LLP as independent public accountants for the company for the fiscal year ending December 31, 2015;
3. to transact any and all other business that may properly come before the meeting.
|